The DOI matches its Crossref record; 145 of the 145 references it cites were found in a registry or an index.
The cancer-immunity cycle: Indication, genotype, and immunotype
Open accessAbstract
The cancer-immunity cycle provides a framework to understand the series of events that generate anti-cancer immune responses. It emphasizes the iterative nature of the response where the killing of tumor cells by T cells initiates subsequent rounds of antigen presentation and T cell stimulation, maintaining active immunity and adapting it to tumor evolution. Any step of the cycle can become rate-limiting, rendering the immune system unable to control tumor growth. Here, we update the cancer-immunity cycle based on the remarkable progress of the past decade. Understanding the mechanism of checkpoint inhibition has evolved, as has our view of dendritic cells in sustaining anti-tumor immunity. We additionally account for the role of the tumor microenvironment in facilitating, not just suppressing, the anti-cancer response, and discuss the importance of considering a tumor's immunological phenotype, the "immunotype". While these new insights add some complexity to the cycle, they also provide new targets for research and therapeutic intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Self-citationPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
Self-citationElements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Self-citationPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Self-citationMolecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
A framework for advancing our understanding of cancer-associated fibroblasts
Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0238-1 · Cited by 3,863
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
B cells and tertiary lymphoid structures promote immunotherapy response
Helmink, B. A., Reddy, S. M., Gao, J., Zhang, S., Basar, R., Thakur, R., Yizhak, K., Sade-Feldman, M., Blando, J., Han, G., et al. (2020) · Nature · doi:10.1038/s41586-019-1922-8 · Cited by 2,731
Dendritic cells in cancer immunology and immunotherapy
Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., & Sancho, D. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0210-z · Cited by 2,574
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301
Elyada, E., Bolisetty, M., Laise, P., Flynn, W. F., Courtois, E. T., Burkhart, R. A., Teinor, J. A., Belleau, P., Biffi, G., Lucito, M. S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0094 · Cited by 2,241
Top 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238
Self-citationMellman, I., & Steinman, R. M. (2001) · Cell · doi:10.1016/s0092-8674(01)00449-4 · Cited by 2,237
Self-citationFeig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Tawbi, H. A., Schadendorf, D., Lipson, E. J., Ascierto, P. A., Matamala, L., Castillo Gutiérrez, E., Rutkowski, P., Gogas, H. J., Lao, C. D., De Menezes, J. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2109970 · Cited by 1,883
Böttcher, J. P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrerizo, M., Sammicheli, S., Rogers, N. C., Sahai, E., Zelenay, S., & Reis e Sousa, C. (2018) · Cell · doi:10.1016/j.cell.2018.01.004 · Cited by 1,857
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
Rojas, L. A., Sethna, Z., Soares, K. C., Olcese, C., Pang, N., Patterson, E., Lihm, J., Ceglia, N., Guasp, P., Chu, A., et al. (2023) · Nature · doi:10.1038/s41586-023-06063-y · Cited by 1,432
Self-citationThe cellular and molecular origin of tumor-associated macrophages
Franklin, R. A., Liao, W., Sarkar, A., Kim, M. V., Bivona, M. R., Liu, K., Pamer, E. G., & Li, M. O. (2014) · Science · doi:10.1126/science.1252510 · Cited by 1,393
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609279 · Cited by 1,368
Biffi, G., Oni, T. E., Spielman, B., Hao, Y., Elyada, E., Park, Y., Preall, J., & Tuveson, D. A. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0710 · Cited by 1,360
Su, S., Chen, J., Yao, H., Liu, J., Yu, S., Lao, L., Wang, M., Luo, M., Xing, Y., Chen, F., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.009 · Cited by 1,230
Clinical and therapeutic relevance of cancer-associated fibroblasts
Chen, Y., McAndrews, K. M., & Kalluri, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00546-5 · Cited by 1,230
Broz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., Rosenblum, M. D., Daud, A., Barber, D. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.007 · Cited by 1,207
Immune checkpoint therapy—current perspectives and future directions
Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B. A., Singh, P., Nagarajan, A., Liu, J., Subudhi, S. K., Poon, C., Gant, K. L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.006 · Cited by 1,206
Dendritic cells in a mature age
Reis e Sousa, C. (2006) · Nature Reviews Immunology · doi:10.1038/nri1845 · Cited by 1,195
The Induction of Tolerance by Dendritic Cells That Have Captured Apoptotic Cells
Steinman, R. M., Turley, S., Mellman, I., & Inaba, K. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.3.411 · Cited by 1,172
Self-citationFibroblasts: Origins, definitions, and functions in health and disease
Plikus, M. V., Wang, X., Sinha, S., Forte, E., Thompson, S. M., Herzog, E. L., Driskell, R. R., Rosenthal, N., Biernaskie, J., & Horsley, V. (2021) · Cell · doi:10.1016/j.cell.2021.06.024 · Cited by 1,141
Salmon, H., Franciszkiewicz, K., Damotte, D., Dieu-Nosjean, M.-C., Validire, P., Trautmann, A., Mami-Chouaib, F., & Donnadieu, E. (2012) · Journal of Clinical Investigation · doi:10.1172/jci45817 · Cited by 1,138
Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T. (2010) · Science · doi:10.1126/science.1195300 · Cited by 1,134
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
Zelenay, S., van der Veen, A. G., Böttcher, J. P., Snelgrove, K. J., Rogers, N., Acton, S. E., Chakravarty, P., Girotti, M. R., Marais, R., Quezada, S. A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.015 · Cited by 1,128
CD8+ T cell differentiation and dysfunction in cancer
Philip, M., & Schietinger, A. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00574-3 · Cited by 1,052
The epigenetic landscape of T cell exhaustion
Sen, D. R., Kaminski, J., Barnitz, R. A., Kurachi, M., Gerdemann, U., Yates, K. B., Tsao, H.-W., Godec, J., LaFleur, M. W., Brown, F. D., et al. (2016) · Science · doi:10.1126/science.aae0491 · Cited by 986
A conserved dendritic-cell regulatory program limits antitumour immunity
Maier, B., Leader, A. M., Chen, S. T., Tung, N., Chang, C., LeBerichel, J., Chudnovskiy, A., Maskey, S., Walker, L., Finnigan, J. P., et al. (2020) · Nature · doi:10.1038/s41586-020-2134-y · Cited by 941
Chromatin states define tumour-specific T cell dysfunction and reprogramming
Philip, M., Fairchild, L., Sun, L., Horste, E. L., Camara, S., Shakiba, M., Scott, A. C., Viale, A., Lauer, P., Merghoub, T., et al. (2017) · Nature · doi:10.1038/nature22367 · Cited by 933
Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma
Patel, S. P., Othus, M., Chen, Y., Wright, G. P., Yost, K. J., Hyngstrom, J. R., Hu-Lieskovan, S., Lao, C. D., Fecher, L. A., Truong, T.-G., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2211437 · Cited by 919
Dominguez, C. X., Müller, S., Keerthivasan, S., Koeppen, H., Hung, J., Gierke, S., Breart, B., Foreman, O., Bainbridge, T. W., Castiglioni, A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0644 · Cited by 857
Self-citationJuneja, V. R., McGuire, K. A., Manguso, R. T., LaFleur, M. W., Collins, N., Haining, W. N., Freeman, G. J., & Sharpe, A. H. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160801 · Cited by 851
Xu, S., Chaudhary, O., Rodríguez-Morales, P., Sun, X., Chen, D., Zappasodi, R., Xu, Z., Pinto, A. F. M., Williams, A., Schulze, I., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.05.003 · Cited by 809
Self-citationZhu, Y., Herndon, J. M., Sojka, D. K., Kim, K.-W., Knolhoff, B. L., Zuo, C., Cullinan, D. R., Luo, J., Bearden, A. R., Lavine, K. J., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.07.014 · Cited by 801
Peripheral T cell expansion predicts tumour infiltration and clinical response
Wu, T. D., Madireddi, S., de Almeida, P. E., Banchereau, R., Chen, Y.-J. J., Chitre, A. S., Chiang, E. Y., Iftikhar, H., O’Gorman, W. E., Au-Yeung, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2056-8 · Cited by 770
Self-citationFatty acid transport protein 2 reprograms neutrophils in cancer
Veglia, F., Tyurin, V. A., Blasi, M., De Leo, A., Kossenkov, A. V., Donthireddy, L., To, T. K. J., Schug, Z., Basu, S., Wang, F., et al. (2019) · Nature · doi:10.1038/s41586-019-1118-2 · Cited by 751
Clinical relevance of tumour-associated macrophages
Pittet, M. J., Michielin, O., & Migliorini, D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00620-6 · Cited by 731
Ebert, P. J. R., Cheung, J., Yang, Y., McNamara, E., Hong, R., Moskalenko, M., Gould, S. E., Maecker, H., Irving, B. A., Kim, J. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.024 · Cited by 713
Self-citationWallin, J. J., Bendell, J. C., Funke, R., Sznol, M., Korski, K., Jones, S., Hernandez, G., Mier, J., He, X., Hodi, F. S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12624 · Cited by 713
Self-citationCross-tissue single-cell landscape of human monocytes and macrophages in health and disease
Mulder, K., Patel, A. A., Kong, W. T., Piot, C., Halitzki, E., Dunsmore, G., Khalilnezhad, S., Irac, S. E., Dubuisson, A., Chevrier, M., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.07.007 · Cited by 678
CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions
Hashimoto, M., Kamphorst, A. O., Im, S. J., Kissick, H. T., Pillai, R. N., Ramalingam, S. S., Araki, K., & Ahmed, R. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-012017-043208 · Cited by 656
Chakravarthy, A., Khan, L., Bensler, N. P., Bose, P., & De Carvalho, D. D. (2018) · Nature Communications · doi:10.1038/s41467-018-06654-8 · Cited by 656
Kumar, V., Donthireddy, L., Marvel, D., Condamine, T., Wang, F., Lavilla-Alonso, S., Hashimoto, A., Vonteddu, P., Behera, R., Goins, M. A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.005 · Cited by 653
Powles, T., Csőszi, T., Özgüroğlu, M., Matsubara, N., Géczi, L., Cheng, S. Y.-S., Fradet, Y., Oudard, S., Vulsteke, C., Morales Barrera, R., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00152-2 · Cited by 643
Self-citationVanhersecke, L., Brunet, M., Guégan, J.-P., Rey, C., Bougouin, A., Cousin, S., Le Moulec, S., Besse, B., Loriot, Y., Larroquette, M., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00232-6 · Cited by 632
Tissue‐resident macrophages provide a pro‐tumorigenic niche to early NSCLC cells
Casanova-Acebes, M., Dalla, E., Leader, A. M., LeBerichel, J., Nikolic, J., Morales, B. M., Brown, M., Chang, C., Troncoso, L., Chen, S. T., et al. (2021) · Nature · doi:10.1038/s41586-021-03651-8 · Cited by 629
Inaba, K., Turley, S., Yamaide, F., Iyoda, T., Mahnke, K., Inaba, M., Pack, M., Subklewe, M., Sauter, B., Sheff, D., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.11.2163 · Cited by 623
Self-citationFibroblasts as immune regulators in infection, inflammation and cancer
Davidson, S., Coles, M., Thomas, T., Kollias, G., Ludewig, B., Turley, S., Brenner, M., & Buckley, C. D. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00540-z · Cited by 605
Self-citationPowles, T., Kockx, M., Rodriguez-Vida, A., Duran, I., Crabb, S. J., Van Der Heijden, M. S., Szabados, B., Pous, A. F., Gravis, G., Herranz, U. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0628-7 · Cited by 591
Self-citationA timeline of tumour-associated macrophage biology
Cassetta, L., & Pollard, J. W. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00547-1 · Cited by 581
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
Rohaan, M. W., Borch, T. H., van den Berg, J. H., Met, Ö., Kessels, R., Geukes Foppen, M. H., Stoltenborg Granhøj, J., Nuijen, B., Nijenhuis, C., Jedema, I., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2210233 · Cited by 568
Huang, H., Wang, Z., Zhang, Y., Pradhan, R. N., Ganguly, D., Chandra, R., Murimwa, G., Wright, S., Gu, X., Maddipati, R., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.011 · Cited by 542
Self-citationStromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer
Ligorio, M., Sil, S., Malagon-Lopez, J., Nieman, L. T., Misale, S., Di Pilato, M., Ebright, R. Y., Karabacak, M. N., Kulkarni, A. S., Liu, A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.012 · Cited by 528
Dizman, N., Meza, L., Bergerot, P., Alcantara, M., Dorff, T., Lyou, Y., Frankel, P., Cui, Y., Mira, V., Llamas, M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01694-6 · Cited by 515
An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors
Reinhard, K., Rengstl, B., Oehm, P., Michel, K., Billmeier, A., Hayduk, N., Klein, O., Kuna, K., Ouchan, Y., Wöll, S., et al. (2020) · Science · doi:10.1126/science.aay5967 · Cited by 512
Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
Lo, A., Wang, L.-C. S., Scholler, J., Monslow, J., Avery, D., Newick, K., O'Brien, S., Evans, R. A., Bajor, D. J., Clendenin, C., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3041 · Cited by 498
Cytotoxic CD4+ T cells in cancer: Expanding the immune effector toolbox
Oh, D. Y., & Fong, L. (2021) · Immunity · doi:10.1016/j.immuni.2021.11.015 · Cited by 467
Cho, B. C., Abreu, D. R., Hussein, M., Cobo, M., Patel, A. J., Secen, N., Lee, K. H., Massuti, B., Hiret, S., Yang, J. C. H., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00226-1 · Cited by 463
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer
Oh, S. A., Wu, D.-C., Cheung, J., Navarro, A., Xiong, H., Cubas, R., Totpal, K., Chiu, H., Wu, Y., Comps-Agrar, L., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0075-x · Cited by 459
Self-citationCD8+ T cells in the cancer-immunity cycle
Giles, J. R., Globig, A.-M., Kaech, S. M., & Wherry, E. J. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.005 · Cited by 449
Liu, L., Mayes, P. A., Eastman, S., Shi, H., Yadavilli, S., Zhang, T., Yang, J., Seestaller-Wehr, L., Zhang, S.-Y., Hopson, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2339 · Cited by 446
Li, W., Tanikawa, T., Kryczek, I., Xia, H., Li, G., Wu, K., Wei, S., Zhao, L., Vatan, L., Wen, B., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.04.022 · Cited by 446
LRRC15(+) myofibroblasts dictate the stromal setpoint to suppress tumour immunity
Krishnamurty, A. T., Shyer, J. A., Thai, M., Gandham, V., Buechler, M. B., Yang, Y. A., Pradhan, R. N., Wang, A. W., Sanchez, P. L., Qu, Y., et al. (2022) · Nature · doi:10.1038/s41586-022-05272-1 · Cited by 436
Self-citationMagen, A., Hamon, P., Fiaschi, N., Soong, B. Y., Park, M. D., Mattiuz, R., Humblin, E., Troncoso, L., D’souza, D., Dawson, T., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02345-0 · Cited by 429
Macrophages at the interface of the co-evolving cancer ecosystem
Kloosterman, D. J., & Akkari, L. (2023) · Cell · doi:10.1016/j.cell.2023.02.020 · Cited by 427
Dendritic Cell Function in Vivo during the Steady State: A Role in Peripheral Tolerance
STEINMAN, R. M., HAWIGER, D., LIU, K., BONIFAZ, L., BONNYAY, D., MAHNKE, K., IYODA, T., RAVETCH, J., DHODAPKAR, M., INABA, K., et al. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb06029.x · Cited by 426
Activated fibroblasts in cancer: Perspectives and challenges
Caligiuri, G., & Tuveson, D. A. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.015 · Cited by 424
Youngblood, B., Oestreich, K. J., Ha, S.-J., Duraiswamy, J., Akondy, R. S., West, E. E., Wei, Z., Lu, P., Austin, J. W., Riley, J. L., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.06.015 · Cited by 419
Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
Patil, N. S., Nabet, B. Y., Müller, S., Koeppen, H., Zou, W., Giltnane, J., Au-Yeung, A., Srivats, S., Cheng, J. H., Takahashi, C., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.02.002 · Cited by 408
Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics
Puré, E., & Blomberg, R. (2018) · Oncogene · doi:10.1038/s41388-018-0275-3 · Cited by 391
Androgen receptor activity in T cells limits checkpoint blockade efficacy
Guan, X., Polesso, F., Wang, C., Sehrawat, A., Hawkins, R. M., Murray, S. E., Thomas, G. V., Caruso, B., Thompson, R. F., Wood, M. A., et al. (2022) · Nature · doi:10.1038/s41586-022-04522-6 · Cited by 391
Overcoming TGFβ-mediated immune evasion in cancer
Tauriello, D. V. F., Sancho, E., & Batlle, E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00413-6 · Cited by 377
Insights Gained from Single-Cell Analysis of Immune Cells in the Tumor Microenvironment
Ren, X., Zhang, L., Zhang, Y., Li, Z., Siemers, N., & Zhang, Z. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-110519-071134 · Cited by 370
Banta, K. L., Xu, X., Chitre, A. S., Au-Yeung, A., Takahashi, C., O’Gorman, W. E., Wu, T. D., Mittman, S., Cubas, R., Comps-Agrar, L., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.02.005 · Cited by 370
Self-citationGrout, J. A., Sirven, P., Leader, A. M., Maskey, S., Hector, E., Puisieux, I., Steffan, F., Cheng, E., Tung, N., Maurin, M., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1714 · Cited by 366
Self-citationProkhnevska, N., Cardenas, M. A., Valanparambil, R. M., Sobierajska, E., Barwick, B. G., Jansen, C., Reyes Moon, A., Gregorova, P., delBalzo, L., Greenwald, R., et al. (2023) · Immunity · doi:10.1016/j.immuni.2022.12.002 · Cited by 365
Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer
Kersten, K., Hu, K. H., Combes, A. J., Samad, B., Harwin, T., Ray, A., Rao, A. A., Cai, E., Marchuk, K., Artichoker, J., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.05.004 · Cited by 349
Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy
Barrett, R. L., & Puré, E. (2020) · eLife · doi:10.7554/elife.57243 · Cited by 346
LAG-3 as the third checkpoint inhibitor
Aggarwal, V., Workman, C. J., & Vignali, D. A. A. (2023) · Nature Immunology · doi:10.1038/s41590-023-01569-z · Cited by 341
Cancer-associated fibroblasts lead tumor invasion through integrin-β3–dependent fibronectin assembly
Attieh, Y., Clark, A. G., Grass, C., Richon, S., Pocard, M., Mariani, P., Elkhatib, N., Betz, T., Gurchenkov, B., & Vignjevic, D. M. (2017) · Journal of Cell Biology · doi:10.1083/jcb.201702033 · Cited by 338
Wood, C., Srivastava, P., Bukowski, R., Lacombe, L., Gorelov, A. I., Gorelov, S., Mulders, P., Zielinski, H., Hoos, A., Teofilovici, F., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60697-2 · Cited by 332
Tertiary lymphoid structures and B cells: An intratumoral immunity cycle
Fridman, W. H., Meylan, M., Pupier, G., Calvez, A., Hernandez, I., & Sautès-Fridman, C. (2023) · Immunity · doi:10.1016/j.immuni.2023.08.009 · Cited by 326
Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
Topalian, S. L., Forde, P. M., Emens, L. A., Yarchoan, M., Smith, K. N., & Pardoll, D. M. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.011 · Cited by 317
Dendritic cells as shepherds of T cell immunity in cancer
Pittet, M. J., Di Pilato, M., Garris, C., & Mempel, T. R. (2023) · Immunity · doi:10.1016/j.immuni.2023.08.014 · Cited by 313
(2022) · doi:10.1158/2159-8290.cd-20-1484 · Cited by 311
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy
Fujiwara, Y., Kato, S., Nesline, M. K., Conroy, J. M., DePietro, P., Pabla, S., & Kurzrock, R. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102461 · Cited by 304
Functional states of myeloid cells in cancer
van Vlerken-Ysla, L., Tyurina, Y. Y., Kagan, V. E., & Gabrilovich, D. I. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.009 · Cited by 261
Powles, T., Yuen, K. C., Gillessen, S., Kadel, E. E., Rathkopf, D., Matsubara, N., Drake, C. G., Fizazi, K., Piulats, J. M., Wysocki, P. J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01600-6 · Cited by 256
Self-citationElkrief, A., Derosa, L., Kroemer, G., Zitvogel, L., & Routy, B. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz206 · Cited by 246
Cancer Associated Fibroblasts: The Architects of Stroma Remodeling
Santi, A., Kugeratski, F. G., & Zanivan, S. (2018) · PROTEOMICS · doi:10.1002/pmic.201700167 · Cited by 244
Transforming growth factor–β1 in regulatory T cell biology
Moreau, J. M., Velegraki, M., Bolyard, C., Rosenblum, M. D., & Li, Z. (2022) · Science Immunology · doi:10.1126/sciimmunol.abi4613 · Cited by 243
Visualizing Synaptic Transfer of Tumor Antigens among Dendritic Cells
Ruhland, M. K., Roberts, E. W., Cai, E., Mujal, A. M., Marchuk, K., Beppler, C., Nam, D., Serwas, N. K., Binnewies, M., & Krummel, M. F. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.05.002 · Cited by 240
Helms, E. J., Berry, M. W., Chaw, R. C., DuFort, C. C., Sun, D., Onate, M. K., Oon, C., Bhattacharyya, S., Sanford-Crane, H., Horton, W., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0601 · Cited by 238
Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas
Friedrich, M., Sankowski, R., Bunse, L., Kilian, M., Green, E., Ramallo Guevara, C., Pusch, S., Poschet, G., Sanghvi, K., Hahn, M., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00201-z · Cited by 226
Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity
Ma, L., Hostetler, A., Morgan, D. M., Maiorino, L., Sulkaj, I., Whittaker, C. A., Neeser, A., Pires, I. S., Yousefpour, P., Gregory, J., et al. (2023) · Cell · doi:10.1016/j.cell.2023.06.002 · Cited by 220
Systemic vaccination induces CD8+ T cells and remodels the tumor microenvironment
Baharom, F., Ramirez-Valdez, R. A., Khalilnezhad, A., Khalilnezhad, S., Dillon, M., Hermans, D., Fussell, S., Tobin, K. K. S., Dutertre, C.-A., Lynn, G. M., et al. (2022) · Cell · doi:10.1016/j.cell.2022.10.006 · Cited by 219
Targeting innate immune pathways for cancer immunotherapy
Cao, L. L., & Kagan, J. C. (2023) · Immunity · doi:10.1016/j.immuni.2023.07.018 · Cited by 216
Pal, S. K., Albiges, L., Tomczak, P., Suárez, C., Voss, M. H., de Velasco, G., Chahoud, J., Mochalova, A., Procopio, G., Mahammedi, H., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00922-4 · Cited by 211
Self-citationBayerl, F., Meiser, P., Donakonda, S., Hirschberger, A., Lacher, S. B., Pedde, A.-M., Hermann, C. D., Elewaut, A., Knolle, M., Ramsauer, L., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.05.011 · Cited by 203
Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells
Baharom, F., Ramirez-Valdez, R. A., Tobin, K. K. S., Yamane, H., Dutertre, C.-A., Khalilnezhad, A., Reynoso, G. V., Coble, V. L., Lynn, G. M., Mulè, M. P., et al. (2021) · Nature Immunology · doi:10.1038/s41590-020-00810-3 · Cited by 202
Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts
Kerdidani, D., Aerakis, E., Verrou, K.-M., Angelidis, I., Douka, K., Maniou, M.-A., Stamoulis, P., Goudevenou, K., Prados, A., Tzaferis, C., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20210815 · Cited by 196
Duraiswamy, J., Turrini, R., Minasyan, A., Barras, D., Crespo, I., Grimm, A. J., Casado, J., Genolet, R., Benedetti, F., Wicky, A., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.10.008 · Cited by 190
Androgen receptor-mediated CD8+ T cell stemness programs drive sex differences in antitumor immunity
Yang, C., Jin, J., Yang, Y., Sun, H., Wu, L., Shen, M., Hong, X., Li, W., Lu, L., Cao, D., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.012 · Cited by 189
Nixon, B. G., Kuo, F., Ji, L., Liu, M., Capistrano, K., Do, M., Franklin, R. A., Wu, X., Kansler, E. R., Srivastava, R. M., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.002 · Cited by 187
Delacher, M., Simon, M., Sanderink, L., Hotz-Wagenblatt, A., Wuttke, M., Schambeck, K., Schmidleithner, L., Bittner, S., Pant, A., Ritter, U., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.03.007 · Cited by 164
Koncina, E., Nurmik, M., Pozdeev, V. I., Gilson, C., Tsenkova, M., Begaj, R., Stang, S., Gaigneaux, A., Weindorfer, C., Rodriguez, F., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39953-w · Cited by 159
Schwörer, S., Cimino, F. V., Ros, M., Tsanov, K. M., Ng, C., Lowe, S. W., Carmona‐Fontaine, C., & Thompson, C. B. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2316 · Cited by 158
Klemm, F., Möckl, A., Salamero‐Boix, A., Alekseeva, T., Schäffer, A., Schulz, M., Niesel, K., Maas, R. R., Groth, M., Elie, B. T., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00254-0 · Cited by 152
ESCRT-mediated membrane repair protects tumor-derived cells against T cell attack
Ritter, A. T., Shtengel, G. E., Xu, C. S., Weigel, A. V., Hoffman, D. P., Freeman, M., Iyer, N., Alivodej, N., Ackerman, D., Voskoboinik, I., et al. (2022) · Science · doi:10.1126/science.abl3855 · Cited by 152
Self-citationControl of tumor-associated macrophage responses by nutrient acquisition and metabolism
Zhang, X., Ji, L., & Li, M. O. (2023) · Immunity · doi:10.1016/j.immuni.2022.12.003 · Cited by 146
Molecular Pathways: Deciphering Mechanisms of Resistance to Macrophage-Targeted Therapies
Quail, D. F., & Joyce, J. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0133 · Cited by 142
Innate immune detection of lipid oxidation as a threat assessment strategy
Zhivaki, D., & Kagan, J. C. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00618-8 · Cited by 136
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
Vellano, C. P., White, M. G., Andrews, M. C., Chelvanambi, M., Witt, R. G., Daniele, J. R., Titus, M. A., McQuade, J. L., Conforti, F., Burton, E. M., et al. (2022) · Nature · doi:10.1038/s41586-022-04833-8 · Cited by 136
Ford, B. R., Vignali, P., Rittenhouse, N., Scharping, N. E., Peralta, R. M., Lontos, K., Frisch, A. T., Delgoffe, G. M., & Poholek, A. C. (2022) · Science Immunology · doi:10.1126/sciimmunol.abj9123 · Cited by 125
Cancer cell-intrinsic mechanisms driving acquired immune tolerance
Ghorani, E., Swanton, C., & Quezada, S. A. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.004 · Cited by 124
Powles, T. B., Sridhar, S. S., Loriot, Y., Bellmunt, J., Mu, X. J., Ching, K. A., Pu, J., Sternberg, C. N., Petrylak, D. P., Tambaro, R., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01579-0 · Cited by 122
Self-citationExpanding dendritic cell nomenclature in the single-cell era
Ginhoux, F., Guilliams, M., & Mérad, M. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00675-7 · Cited by 115
Castiglioni, A., Yang, Y., Williams, K., Gogineni, A., Lane, R. S., Wang, A. W., Shyer, J. A., Zhang, Z., Mittman, S., Gutierrez, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40398-4 · Cited by 115
Self-citationNguyen, E. V., Pereira, B. A., Lawrence, M. G., Ma, X., Rebello, R. J., Chan, H., Niranjan, B., Wu, Y., Ellem, S., Guan, X., et al. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra119.001496 · Cited by 107
Herzog, B. H., Baer, J. M., Borcherding, N. C., Kingston, N. L., Belle, J. I., Knolhoff, B. L., Hogg, G. D., Ahmad, F. F., Kang, L., Petrone, J., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh8005 · Cited by 103
Hu, Y., Hudson, W. H., Kissick, H. T., Medina, C. B., Baptista, A. P., Ma, C., Liao, W., Germain, R. N., Turley, S. J., Zhang, N., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20211574 · Cited by 92
Self-citationTargeting Solid Tumors with Bispecific T Cell Engager Immune Therapy
Arvedson, T., Bailis, J. M., Britten, C. D., Klinger, M., Nagorsen, D., Coxon, A., Egen, J. G., & Martin, F. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070620-104325 · Cited by 87
Evrard, M., Becht, É., Fonseca, R., Obers, A., Park, S. L., Zanluqui, N. G., Schröder, J., Christo, S. N., Schienstock, D., Lai, J., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.06.005 · Cited by 78
Fibroblasts as Modulators of Local and Systemic Cancer Metabolism
Sanford-Crane, H., Abrego, J., & Sherman, M. H. (2019) · Cancers · doi:10.3390/cancers11050619 · Cited by 77
TGFβ and Retinoic Acid Intersect in Immune-Regulation
Mucida, D., & Cheroutre, H. (2007) · Cell Adhesion & Migration · doi:10.4161/cam.1.3.5062 · Cited by 68
Within tumors, interactions between T cells and tumor cells are impeded by the extracellular matrix
Salmon, H., & Donnadieu, E. (2012) · OncoImmunology · doi:10.4161/onci.20239 · Cited by 67
Conde, E., Vercher, E., Soria-Castellano, M., Suárez-Olmos, J., Mancheño, U., Elizalde, E., Rodriguez, M. L., Glez‐Vaz, J., Casares, N., Rodríguez‐García, E., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003351 · Cited by 67
In situ tumour arrays reveal early environmental control of cancer immunity
Ortiz-Muñoz, G., Brown, M. K., Carbone, C. B., Pechuan-Jorge, X., Rouilly, V., Lindberg, H., Ritter, A. T., Raghupathi, G., Sun, Q., Nicotra, T., et al. (2023) · Nature · doi:10.1038/s41586-023-06132-2 · Cited by 52
Self-citationZuo, C., Baer, J. M., Knolhoff, B. L., Belle, J. I., Liu, X., de la Lastra, A. A., Fu, C. F., Hogg, G. D., Kingston, N. L., Breden, M. A., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20212062 · Cited by 50
Tumor and local lymphoid tissue interaction determines prognosis in high-grade serous ovarian cancer
Lu, H., Lou, H., Wengert, G., Paudel, R., Patel, N. R., Desai, S., Crum, B., Linton‐Reid, K., Chen, M., Li, D., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101092 · Cited by 50
Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapy
Singh, N., & Maus, M. V. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.010 · Cited by 47
PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer
Ali, L. R., Garrido-Castro, A. C., Lenehan, P. J., Böllenrücher, N., Stump, C. T., Dougan, M. L., Goel, S., Shapiro, G. I., Tolaney, S. M., & Dougan, S. K. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20220729 · Cited by 44
Paschen, A., Melero, I., & Ribas, A. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070220-111016 · Cited by 34
Exploiting Canonical TGFβ Signaling in Cancer Treatment
Liu, Q., Chen, G., Moore, J., Guix, I., Placantonakis, D., & Barcellos-Hoff, M. H. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0891 · Cited by 27
PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets
Chocarro, L., Blanco, E., Fernández, L., Garnica, M., Zuazo, M., Garcia, M. J., Bocanegra, A., Echaide, M., Johnston, C. M., Edwards, C., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00098-y · Cited by 22
On the Biology and Therapeutic Modulation of Macrophages and Dendritic Cells in Cancer
Park, M. D., Belabed, M., Chen, S. T., Hamon, P., Hegde, S., Mattiuz, R., Marron, T. U., & Mérad, M. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061521-085949 · Cited by 18
Cited by
Breast cancer: pathogenesis and treatments
Xiong, X., Zheng, L.-W., Ding, Y., Chen, Y.-F., Cai, Y.-W., Wang, L.-P., Huang, L., Liu, C.-C., Shao, Z.-M., & Yu, K.-D. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02108-4 · Cited by 958
The interaction of innate immune and adaptive immune system
Wang, R., Lan, C., Benlagha, K., Camara, N. O. S., Miller, H., Kubo, M., Heegaard, S., Lee, P., Yang, L., Forsman, H., et al. (2024) · MedComm · doi:10.1002/mco2.714 · Cited by 305
Cancer immune evasion, immunoediting and intratumour heterogeneity
Roerden, M., & Spranger, S. (2025) · Nature Reviews Immunology · doi:10.1038/s41577-024-01111-8 · Cited by 265
Metabolic reprogramming in the tumor microenvironment of liver cancer
Lin, J., Rao, D., Zhang, M., & Gao, Q. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01527-8 · Cited by 251
“Metabolic derangements within the TME are increasingly recognized as one of the most important factors halting the CIC [94].”
BackgroundAdvances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Metadata
- Authors
- Mellman, I., Chen, D. S., Powles, T., & Turley, S. J.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2023-10
- Volume
- 56
- Issue
- 10
- Pages
- 2188-2205
- ISSN
- 1074-7613 (ISSN-L)
- OpenAlex
- W4387494986
- Cited by
- 953
- References
- 145
- FWCI
- 98.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.